secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001628280-23-035600
Event type: m_and_a
Sentiment:  positive
Materiality: 0.55
Item codes: 2.01, 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo completes divestiture of AVTX-800 series for $150K upfront, up to $45M milestones
--------------------------------------------------------------------------------

- Upfront payment of $150,000 from AUG; AUG assumed $150,000 of pre-closing liabilities.
- Potential aggregate milestone payments of $45M ($15M per compound) upon first FDA approval for non-Rare Pediatric Disease.
- AUG to share up to 20% of net proceeds from any future sale of priority review vouchers.
- CEO states pipeline now focused on core immunology assets; transaction immediately improves cash flow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023035600/0001628280-23-035600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023035600/avtx-20231027.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-035600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer